More than 60,000 patients in the Czech Republic use blood plasma-derived medicines. The Rare Diseases Czech Republic (known locally as ČAVO) established a patient working group in 2024, followed by the launch of a dedicated portal www.plazmaticke-proteiny.cz in April 2025.

Plasma proteins play a vital role in modern medicine – for both acute medical conditions and long-term treatment of chronic or rare diseases such as primary (PID) and secondary immunodeficiency (SID), hereditary angioedema (HAE), CIDP and others.

Join the Plasma Protein Users Working Group (PUPP) 

Since plasma-derived medications can also be used for acute and prophylactic treatment of HAE, Czech HAE patients/caregivers are kindly invited to join the Plasma protein users working group (PUPP). It aims to encourage the mutual sharing of patients' experience, to map their needs and to work together on improving the availability of plasma-derived drugs within the Czech and European legislation. "Our vision is to make the voice of patients an important part of decision-making processes in the Czech Republic and the EU," comments Camelia Isaic, working group leader.

To join the PUPP working group, please fill in the registration form.

Visit the new awareness website

The new website plasmaticke-proteiny.cz was launched as an initiative of the PUPP patient working group. The online portal features (in Czech) patient stories, interviews with experts, information on awareness campaigns about diseases for which these therapies are relevant, etc.

For more information about the new platform in Czech, visit: https://vzacna-onemocneni.cz/akt-spoustime-novou-online-platformu-o-plazmatickych-proteinech/#more-18186